Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:50:02 EDT Wed 23 Apr 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:IPHA - INNATE PHARMA SPON ADS EACH REP 1 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IPHA - Q2.51.79·2.392.01.9955+0.073.661.21091752.10  2.19  1.963.5107  1.2916:00:0301:0015 min RT 2¢

Recent Trades - Last 10 of 175
Time ETExPriceChangeVolume
16:00:03Q1.970.014
15:59:35Q1.980.0291
15:59:30Q1.990.034
15:59:17Q1.990.032
15:58:37Q1.990.033
15:58:15Q1.990.0350
15:57:37Q1.970.013
15:57:25Q1.990.0330
15:57:25Q1.990.0331
15:56:16Q1.9650.0053

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-04-23 01:00U:IPHANews ReleaseInnate Pharma Regains Its Rights on CD123 Targeting ANKET(TM) and Announces Sanofi's Intention to Make a Strategic Investment in the Company
2025-04-16 01:00U:IPHANews ReleaseInnate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
2025-04-16 01:00U:IPHANews ReleaseInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
2025-04-03 01:00U:IPHANews ReleaseInnate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
2025-03-27 02:00U:IPHANews ReleaseInnate Pharma Reports Full Year 2024 Financial Results and Business Update
2025-03-26 02:00U:IPHANews ReleaseInnate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
2025-03-20 02:00U:IPHANews ReleaseInnate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
2025-02-27 01:00U:IPHANews ReleaseInnate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
2025-02-17 01:02U:IPHANews ReleaseInnate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sezary Syndrome
2025-01-27 01:00U:IPHANews ReleaseInnate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
2025-01-21 01:00U:IPHANews ReleaseInnate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
2025-01-16 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of December 31, 2024
2025-01-10 01:00U:IPHANews ReleaseInnate Pharma Announces Transformative Strategy to Accelerate Growth
2024-12-20 01:00U:IPHANews ReleaseInnate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-09 01:00U:IPHANews ReleaseInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
2024-12-06 01:00U:IPHANews ReleaseInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
2024-12-03 01:00U:IPHANews ReleaseInnate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
2024-11-20 01:00U:IPHANews ReleaseInnate Pharma Releases Its 2025 Financial Calendar
2024-11-19 01:00U:IPHANews ReleaseInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET(TM) IPH6501
2024-11-13 01:00U:IPHANews ReleaseInnate Pharma Reports Third Quarter 2024 Business Update and Financial Results